We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Test Developed for Sickle Cell Anemia

By LabMedica International staff writers
Posted on 20 Sep 2011
A new blood test is being developed, which, for the first time, could help identify babies at risk of a severe form of sickle cell disease. More...


Babies with sickle cell disease have abnormal red blood cells and the test works by detecting these cells, which burst under certain conditions allowing an immediate diagnosis and more intensive treatment to be given.

Scientists from British Universities are collaborating to replace the diagnostic tests for sickle cell disease, which are complicated, requiring skilled technicians, and sophisticated and expensive equipment. Those tests are time consuming and are often not useful in an emergency situation. The newer test involves mixing a blood sample with a special sugar solution in low oxygen. Red blood cells from a baby who has sickle cell disease burst in the liquid, which becomes pink. Cells from a healthy baby do not burst, and the liquid stays clear.

None of the existing tests can predict how severe a baby's illness is likely to be. Babies who are at risk of the most severe symptoms, who might benefit greatly from early and intensive treatment, cannot be easily identified before they become poorly. Children with sickle cell disease face a lifetime of ill health. They have attacks of intense pain called crises, which can last several days. They are prone to infections and anemia, which can be life threatening. They are at risk of a variety of complications, including organ failure, strokes, and leg ulcers, and they have a shortened life expectancy.

An estimated 20 million people are affected worldwide and over 12,000 people in the UK have sickle cell disease, the country's most common severe genetic disorder. Symptoms usually start early in babies who are just six to nine months old. John Gibson, PhD, from the University of Cambridge (UK) is the project leader and working with colleagues at King's College Hospital, (London, UK) have enrolled 120 children and adults with sickle cell disease who will donate blood samples for testing. He said, "The aim of this project is to perfect the diagnostic test, so it can be used routinely at the bedside".

Related Links:
University of Cambridge
King's College Hospital


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.